Our team will be present at Swiss Biotech Day.
– Swiss Biotech Day | 22-23 April 2024 in Basel, Switzerlan
Menu
Our expertise in translational pharmacology
Inoviem offers translational target discovery and drug-target Mode of Action (MoA) based on proprietary label-free technologies, developed in a pathological and physiological environment, that uses human tissue.
Technology
Inoviem provides breakthrough protein technologies for each phase of the drug development process.
One of the major advantages of our label-free technologies used under physiological conditions and in human tissue – NPOT® and PIMS® – is that the test compound retains its original structure, as well as the exact same molecular structure that would be used in therapy
About us
Inoviem, a bioanalytical Contract Research Organization (CRO), enables drug developers to gain greater precision in the understanding of a compound’s clinical Mode of Action (MoA), so that a drug candidate can move rapidly to clinical trials.
Our mission
Our approach is based on the simple idea that current technologies fail to take into account the natural environment in which a drug will have its beneficial effect…
Our values
Inoviem Scientific’s core values are deeply ingrained in our past, present and future; they guide us in our daily work…
